Epidemiology and clinical significance of hepatotropic infections in dialysis patients: Recent evidence

Minerva Urologica e Nefrologica

Volumn 56, Issue 3, 2004, Pages 249-257

  Fabrizi, F ^a,b   Bunnapradist, S ^b   Lunghi, G ^a   Aucella, F ^c   Martin, P ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c IRCCS   (Italy)

Author keywords

Epidemiology; Hepatitis B virus; Hepatitis C virus; Renal dialysis

Indexed keywords

ALPHA2B INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; INTERFERON; INTERLEUKIN 2; LAMIVUDINE; LEVAMISOLE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RECOMBINANT GAMMA INTERFERON; RIBAVIRIN; THYMOPENTIN; VIRUS ANTIBODY; VIRUS DNA; ZINC;

CLINICAL TRIAL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOLYTIC ANEMIA; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; INDUSTRIALIZATION; LIVER DYSFUNCTION; LONG TERM CARE; MAINTENANCE THERAPY; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; NEUROTOXICITY; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT PLANNING;

HEPATITIS B; HEPATITIS C; HUMANS; RENAL DIALYSIS;

EID: 4544288377     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Fabrizi F, Martin P. GBV-C/HGV infection in end-stage renal disease. J Nephrol 1999;12:131-9.
2. Fabrizi F, Martin P, Lunghi G, Locatelli F. TT virus infection in end-stage renal disease. J Nephrol 2001;14:80-7.
3. Kobayashi N, Tanaka E, Umemura T, Matsumoto A, Iijima T, Higuchi M et al. Clinical significance of SEN virus infection in patients on maintenance haemodialysis. Nephrol Dial Transplant 2003;18:348-52.
4. Salama G, Rostaing L, Sandres K, Izopet J. Hepatitis C virus infection in French hemodialysis units: a multicenter study. J Med Virol 2000;61:44-51.
5. Tokars JI, Frank M, Alter MJ, Arduino M. National surveillance of dialysis-associated diseases in the United States, 2000. Sem Dial 2002;15:162-71.
6. Petrosillo N, Gilli P, Serraino D, Dentico P, Mele A, Ragni P et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis 2001;37:1004-10.
7. Lombardi M, Cerrai T, Geatti S, Negroni S, Pertusini L, Pegoraro M et al. Results of a national epidemiological investigation on HCV infection among dialysis patients. J Nephrol 1999;12:322-7.
8. Schneeberger PM, Keur I, van Loon AM, Mortier D, Op de Coul K, Verschuuren-van Haperen A et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis 2000;182:1291-9.
9. Saab S, Martin P, Brezina M, Gitnick G, Yee HF, Serum alanine aminotransferase in hepatitis C screening of patients on hemodialysis. Am J Kidney Dis 2001;37:308-15.
10. Todorov V, Boneva R, llieva P, Doichinova T, Donchev M. High prevalence of hepatitis C virus infection in Bulgariaa. Nephron 1998;79:222-3.
11. Covic A, lancu L, Apetrei C, Scripcaru D, Volovat C, Mititiuc I et al. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant 1999;14:40-5.
12. Hassan AA, Khalil R. Hepatitis C in dialysis patients in Egypt: relationship to dialysis duration, blood transfusion, and liver disease. Saudi J Kidney Dis Transplant 2000;11:72-5.
13. Taskapan H, Oymak O, Dogukan A, Utas C. Patient to patient transmission of hepatitis C virus in hemodialysis units. Clin Nephrol 2001;55:477-81.
14. Jaiswal SP, Chitnis DS, Salgia P, Sepaha A, Pandit CS. Prevalence of hepatitis viruses among chronic renal failure patients on hemodialysis in Central India. Dial Transplant 2002;12:14-20.
15. Valtuille R, Moretto H, Lef L, Rendo P, Fernandez JL. Decline of high hepatitis C virus prevalence in a hemodialysis unit with no isolation measures during a 6-year follow-up. Clin Nephrol 2002;57:371-5.
16. Shaheen FA, Huraib SO, Al-Rashed R, Aldrees A, Arif M, Al-Jeffry M et al. Prevalence of hepatitis C antibodies among hemodialysis patients in Jeddah area, Saudi Arabia. Saudi Med J 2003;2:S125-6.
17. Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A et al. Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000;15:69-80.
18. Espinosa M, Martin-Malo A, Alvarez de Lara MA, Gonzalez R, Rodriguez M, Ajama P. Natural history of acute HCV infection in hemodialysis patients. Clin Nephrol 2002;58:143-50.
19. Stehman-Breen CO, Emerson S, Gretch D, Johson RJ. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998;32:629-34.
20. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000;11:1896-902.
21. Marcelli D, Stanhard D, Conte F, Held PJ, Locatelli F, Port FK. ESRD patient mortality with adjustement for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int 1996;50:1013-8.
22. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999;354:93-9.
23. Ghany MG, Kleiner DE, Alter H, Doo E, Khokar F, Promrat K et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104.
24. Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Vinson S et al. Biological dynamics of viral load in hemodialysis patients with hepatitis C virus. Am J Kidney Dis 2000;35:122-9.
25. Fabrizi F, Martin P, Lunghi G, Ponticelli C. Natural history of hepatitis C virus infection in dialysis. G Ital Nefrol 2003;20:470-7.
26. Fabrizi F, Martin P, Dixit V, Brezina M, Cole MJ, Gerosa S et al. Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. Nephron 1998;80:428-33.
27. Rampino T, Arbustini E, Gregorini M, Guallini P, Libetta C, Maggio M et al. Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor. Kidney Int 1999;56:2286-91.
28. Badalamenti S, Catania A, Lunghi G, Covini G, Bredi E, Brancaccio D et al. Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena? Am J Kidney Dis 2003;42:143-50.
29. Russo MW, Goldsweig CD, Jacobson IM, Brown RS. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003;98:1610-5.
30. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003;18:1071-81.
31. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Ribavinn treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hep 2001;8:287-92.
32. Martin P, Mitra S, Farrington K, Martin NE, Modi WM. Pegylated (40KDA) interferon alfa-2a (Pegasys) is unaffected by renal impairment. Hepatology 2000;32:370A.
33. Mioli VA, Balestra E, Bibiano L, Carletti P, Della Bella S, Fanciulli E et al. Epidemiology of viral hepatitis in dialysis centers: a national survey. Nephron 1992;61:278-83.
34. Oguchi H, Miyasaka M, Tokunaga S, Hora K, Ichikawa S, Ochi T et al. Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 1992;38:36-43.
35. Albertoni F, Battilomo A, Di Nardo V, Franco E, Ippolito G, Marinucci G et al. Evaluation of a region-wide hepatitis B vaccination program in dialysis patients: experience in an Italian region. The Latium Hepatitis Prevention Group. Nephron 1991;58:180-3.
36. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 1997. Semin Dial 2000;13:75-85.
37. Burdick RA, Bragg-Cresham JL, Woods JD, Hedderwick SA, Kurokawa K, Combe C et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int 2003;63:2222-9.
38. Centers for Disease Control and Prevention. Outbreaks of hepatitis B virus infection among hemodialysis patients - California, Nebraska, and Texas. JAMA 1996;275:1394-5.
39. Hutin YJF, Goldstein ST, Varma JK, O'Dair JB, Mast EE, Shapiro CN et al. An outbreak of hospital-acquired hepatitis B virus infection among patients receiving chronic hemodialysis. Infect Control Hosp Epidemiol 1999;20:731-5.
40. CDC. Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus and other blood-borne pathogens in healthcare settings. MMWR 1988;37:377-82.
41. Jankovic N, Cala S, Nadinic B, Varlai-Knobloch V, Pavlovic D. Hepatitis C and hepatitis B virus infection in hemodialysis patients and staff: a two year follow-up. Int J Artif Organs 1994;17:137-40.
42. Cendoroglo-Neto M, Draibe SA, Silva AE, Ferraz ML, Granato C, Pereira CA et al. Incidence and risk factors for hepatitis B and hepatitis C virus infection among haemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant 1995;10:240-6.
43. Teles SA, Martins RMB, Vanderboght B, Stuyver L, Gaspar AMC, Yoshida CFT. Hepatitis B virus: genotypes and subtypes in Brazilian hemodialysis patients. Artif Organs 1999;23:1074-8.
44. Vladutiu D, Cosa A, Neamtu A, State D, Braila M, Gherman M et al. Infection with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map? J Viral Hepat 2000;7:313-9.
45. Otedo AE, Mc'Ligeyo SO, Okoth FA, Kayima JK. Seroprevalence of hepatitis B and C in maintenance dialysis in a public hospital in a developing country. S Afr Med J 2003;93:380-4.
46. Souza KP, Luz JA, Teles SA, Carneiro MA, Oliveira LA, Gomes AS et al. Hepatitis B and C in the hemodialysis unit of Tocantins, Brazil: serological and molecular profiles. Mem Inst Oswaldo Cruz 2003;98:599-603.
47. Josselson J, Kyser BA, Weir MR, Sadler JH. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am J Kidney Dis 1987;6:456-61.
48. Jha R, Kher V, Naik S, Elhence R, Gupta A, Sharma RK. Hepatitis B associated liver disease in dialysis patients: role of vaccination. J Nephrol 1993;6:98-103.
49. Fabrizi F, Mangano S, Alongi G, Bisegna S, Finazzi S, Lunghi G et al. Influence of hepatitis B virus viremia upon serum aminotransferase activity in dialysis population. Int J Artif Organs 2003;26:1048-55.
50. Fabrizi F, Bunnapradist S, Lunghi G, Villa M, Martin P. Transplanting solid organs from HBsAg negative donors positive for antibody to hepatitis B core antigen: the implications. Int J Artif Organs 2003;26:972-83.
51. Duarte R, Huraib S, Said R, Abdel-Khadir A, Sullivan S, Chaballout A et al. Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. Am J Kidney Dis 1995;25:40-5.
52. Schmilovitz-Weiss H, Melzer E, Tur-Kaspa R, Ben-Ari Z. Excellent outcome of lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol 2003;37:64-7.
53. Fontaine H, Thiers V, Chretien Y, Zylberberg H, Poupon RE, Brechot C et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000;69:2090-4.
54. Fabrizi F, Martin P. Hepatitis B vaccine and dialysis: current issues. Int J Artif Organs 2001;24:683-94.